Investigational drug · Phase 2
PP353
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Low-back Pain.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "PP353"
First trial start
2020
Jan 20, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PP353", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Low-back Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "PP353" as an intervention, largest first.
Persica Pharmaceuticals LtdIndustry
NCT04238676 · 43 participants · Start Jan 20, 2020 · Primary completion Dec 9, 2024
Drug: PP353 · For: Chronic Low-back Pain
Sites: Copenhagen, Denmark; Christchurch, New Zealand; Granada, Spain · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Corrigendum to 'Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial' eClinicalMedicine 2026; 92: 103764.
Lassen MR, Scarborough M, Gilchrist N, et al. · EClinicalMedicine 2026
- Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial.
Lassen MR, Scarborough M, Gilchrist N, et al. · EClinicalMedicine 2026
- Preclinical development and characterisation of PP353, a formulation of linezolid for intradiscal administration.
Hagger G, Guest S, Birchall S, et al. · JOR Spine 2024
- Pharmacokinetics of PP353, a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first-in-human, Phase 1b, open-label, single-dose study.
Tripathi SS, Sneath R, Golash A, et al. · JOR Spine 2024
Also in development for Chronic Low-back Pain
- HCP1004Phase 31 trial
Hanmi Pharmaceutical Company Limited · Chronic Low-back Pain
- RLD2401Phase 31 trial
Hanmi Pharmaceutical Company Limited · Chronic Low-back Pain
- CELZ-201-DDTPhase 21 trial
Creative Medical Technology Holdings Inc · Chronic Low-back Pain, Degenerative Disc Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.